Evaluating the safety profile of semaglutide: an updated meta-analysis.

Frederick Berro RiveraEloise Arias-AguirreZedrick AguirreMc John C YbañezJanos Marc M RubiaDanica Janine GalangGrace Nooriza LumbangJade Monica Marie J RuyerasJohn Vincent MagalongPolyn Luz PineJohn Andrew C AmigoMarie Francesca M AnsayNenad ZelenkovSteve Samuel ThomasKrishnaswami Vijayaraghavan

Published in: Current medical research and opinion (2024)

Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations, supporting its continued use in the management of type 2 diabetes mellitus and obesity. It is generally well-tolerated, with a low incidence of adverse events. Clinicians should be aware of these findings and monitor patients accordingly. Further long-term studies are warranted to assess the safety of semaglutide in clinical practice.

Keyphrases

systematic review
clinical practice
ejection fraction
newly diagnosed
metabolic syndrome
insulin resistance
type diabetes
case control
case report
palliative care
randomized controlled trial
patient reported outcomes
weight gain
meta analyses
combination therapy
body mass index
smoking cessation